

**REMARKS**


Paragraph [00043] of the application has been amended to list “transmucosal” delivery as a known drug delivery method. Independent claim 19 has been amended and dependent claim 23 has been newly added to round out the scope of protection afforded by the invention. The application now contains claims 1-23. No new matter has been introduced.

Marked-up versions of the changes made to the specification and claims by the current amendment are attached. The attached pages are captioned “Version With Markings To Show Changes Made To Claims” and “Version With Markings To Show Changes Made To Paragraphs.”

Allowance of this application is respectfully solicited.

Dated: September 24, 2002

Respectfully submitted,

By 

Stephen A. Soffen

Registration No.: 31,063

Gabriela I. Coman

Registration No.: 50,515

DICKSTEIN SHAPIRO MORIN &

OSHINSKY LLP

2101 L Street NW

Washington, DC 20037-1526

(202) 785-9700

Attorneys for Applicant

**Version With Markings to Show Changes Made to Paragraphs**

Please rewrite paragraph [00043] on page 15 of the Specification as follows:

[00043] The opiate antagonist can be administered to the patient by any known drug delivery method (such as transdermal, nasal, transmucosal or intramuscular), however oral administration is preferred. The opiate antagonist may be combined with any pharmaceutically acceptable carrier. For [examples] example, suitable carriers include water, milk, fruit juice and sweetened beverage.

**Version With Markings to Show Changes Made to Claims**

19. (Amended) A method of treating refractory depression characterized by dissociation comprising administering to a patient in need thereof at least one opiate antagonist; evaluating said patient for a response to said opiate antagonist; and reassessing said patient for depression[; and administering at least one antidepressant to said patient].